Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Td
Td vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| group I | EXPERIMENTAL | Tdap |
| group 2 | ACTIVE_COMPARATOR | Td |
| Name | Type | Description |
|---|---|---|
| Tdap | BIOLOGICAL | 0.5 mL IM once at visit #2 |
| Td | BIOLOGICAL | 0.5 mL IM once at visit #2 |
Inclusion Criteria: * Pregnant women 18 years of age and over. * Women who, at ≥30-\<32 weeks gestation, are at low risk for complications as determined by the obstetrical algorithm for identification of eligible subjects and the obstetrical risk assessment form. * Signed, informed consent. Exclus...
Td vaccine is a diphtheria and tetanus combined vaccine for adults and adolescents, given as an adsorbed formulation. It is studied for protection against diphtheria. The recorded clinical program includes a Phase 2 study in pregnant women conducted in Canada.
Sanofi makes the Td vaccine, which is also known as Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed. Sanofi trades under the ticker SNY. The product is a combined diphtheria and tetanus vaccine formulated for adult and adolescent use.
The Td vaccine is in Phase 2 development. Its single recorded trial, NCT00553228, is a completed Phase 2 study. The vaccine is investigational in this program and is being studied in pregnant women for diphtheria protection.
The Td vaccine has been studied in NCT00553228, titled Pertussis Maternal Immunization Study. It was a completed Phase 2 trial that enrolled 320 participants, all female, aged 18 years and older, in Canada. The trial was randomized, double-blind, active-controlled, and enrolled healthy volunteers.